# Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/diarrhea-predominant-irritable-bowel-syndrome-treatment-options-eluxadoline/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael B. Andrews,Douglas G. Adler |
| Citations | 1 |
| DOI | 10.1080/14740338.2025.2490841 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4409245539 |
| PMID | 40197054 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Michael B. Andrews](https://scholariq.org/researchers/michael-b-andrews/)

## Paper journal

- [Expert Opinion on Drug Safety](https://scholariq.org/journals/expert-opinion-on-drug-safety/)

## Paper primary topic

- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)

## Paper topics

- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.